Phase IIb China study of ADC drug targeting TROP2 triple-negative breast cancer reaches its primary endpoint

Article source: Medical Rubik's Cube Info

Author: Sunshine

On November 11, Genting Shinyao and Gilead Sciences jointly announced a phase IIb clinical trial of gosartuzumab (US trade name: Trodelvy) for the treatment of metastatic triple-negative breast cancer (TNBC) (EVER-132-001) Reached its primary endpoint of overall response rate (ORR)

EVER-132-001 is a single-arm, multi-center phase IIb study, which aims to evaluate the treatment of gosartuzumab who has received at least two systemic treatments (at least one of which is for the treatment of metastatic disease) Efficacy of unresectable locally advanced or metastatic triple-negative breast cancer in Chinese adult patients

Triple-negative breast cancer is a highly aggressive type of breast cancer that lacks sufficient estrogen, progesterone and human epidermal growth factor receptor 2 (HER 2), accounting for about 15% of all breast cancer types in the world.

Gosartuzumab is a first-of-its-kind antibody-drug conjugate consisting of an antibody and a topoisomerase inhibitor, and the target is the TROP-2 receptor

Based on data from the Phase III ASCENT study, Trodelvy has been approved for second-line treatment of metastatic triple-negative breast cancer in many countries around the world (including the United States, Australia, Canada, the United Kingdom, Switzerland, etc.

In April 2019, Genting Shining and Gilead reached an authorized introduction agreement and obtained the exclusive rights to develop, register and commercialize gosartuzumab for all cancer indications in Greater China, South Korea and some Southeast Asian countries, and the transaction The total amount exceeds 700 million US dollars

Note: The original text has been deleted